Search

Displaying results 4721 - 4730 of 7018 in total
  1. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    Because Hly is only active at an acidic pH, similar to listeriolysin O, the deletion of urease C was also beneficial for Hly to have optimal bioactivity in the phagosome. … VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other

  2. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  3. Drug

    Epitestosterone

    go.drugbank.com/drugs/DB07768
    Experimental

    Epitestosterone acts as an antiandrogen in various target tissues. The ratio between testosterone/epitestosterone is used to monitor anabolic drug abuse.

  4. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  5. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  6. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. … [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity

  7. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.

  8. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease … It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes.

  9. Drug

    Bisoxatin

    go.drugbank.com/drugs/DB09219
    Approved

    Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine [L926]. … It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.

  10. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).